Sunday, 22 November 2026 SEC EDGAR filings, as they land
ALFAFINDER USA News Straight from the SEC filing
SEC Filings
Nasdaq/NYSE Compliance Warning

Compass Therapeutics Faces Nasdaq Delisting Warning Over $1.00 Minimum Bid Price

Compass Therapeutics, Inc. has entered a period of regulatory non-compliance after its common stock failed to meet the Nasdaq's minimum $1.00 bid price requirement for 30 consecutive business days. The company has been granted a 180-day grace period to rectify the deficiency or risk potential delisting from the exchange.

Tesla, stock, chart, trading. Stock photo illustrating Compass Therapeutics' other story.
Compass Therapeutics, Inc. · Healthcare · Photo: sergeitokmakov / Pixabay

Key highlights

  • Closing bid price remained below $1.00 for 30 consecutive business days ending November 19, 2026
  • Company must achieve a minimum $1.00 closing price for at least 10 consecutive days by May 18, 2027
  • Share price has experienced a significant 72.25% depreciation over the preceding three-month period
  • Management is considering remedial actions including a possible reverse stock split to regain compliance
  • A secondary 180-day extension may be available if the company meets other initial listing standards

What Happened

On November 19, 2026, Compass Therapeutics (CMPX) was formally notified by the Nasdaq Listing Qualifications Department that its common stock failed to maintain the minimum $1.00 bid price required by Listing Rule 5550(a)(2). This notification follows a 30-day period where shares consistently closed below the threshold. The notice currently has no impact on the company's daily operations or its listing status on the Nasdaq Capital Market, where it continues to trade under its existing ticker. The firm has 180 calendar days, ending May 18, 2027, to rectify the situation and maintain its standing on the exchange.

Significance

Regaining compliance requires the stock to close at or above $1.00 for a minimum of ten consecutive business days before the May deadline. If Compass Therapeutics fails to meet this target, it may seek a second 180-day extension, provided it meets other listing standards and expresses intent to cure the deficiency, potentially through a reverse stock split. Failure to regain compliance or qualify for an extension could lead to a delisting determination. While an appeal to a Nasdaq Hearings Panel is possible, such outcomes remain uncertain, and delisting would significantly reduce the stock's liquidity and investor accessibility.

Business Overview

Based in Boston, Massachusetts, Compass Therapeutics is a clinical-stage biotechnology firm dedicated to developing proprietary antibody-based therapeutics. The company's primary focus lies in oncology, where it targets the human immune system to combat various forms of cancer. By leveraging its internal discovery platform, the organization aims to identify and advance novel drug candidates that can either stimulate an immune response or inhibit immunosuppressive pathways. As an emerging growth company, Compass maintains a specialized focus on high-need therapeutic areas within the competitive biotechnology landscape, operating out of its Guest Street headquarters.

Market and Technical Performance

  • Common stock price declined to $0.6882 as of the latest reporting date
  • Market capitalization remains at $123.9 million despite recent share pressure
  • Relative Strength Index is currently at 37.3, reflecting a period of intense selling
  • Total quarterly share price depreciation reached 72.25% as of November 2026
  • Average weekly trading volume for CMPX shares is approximately 2.04 million
Compass Therapeutics, Inc. · financial snapshot
Share price$0.69
Market cap$124M
1-month price change-15.56%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Compass Therapeutics, Inc. announcing its receipt of a Nasdaq deficiency notice regarding minimum bid price.

Read the filing ↗

Track Compass Therapeutics, Inc. live

Get the next Compass Therapeutics, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.